Drug WatchNew Treatment for BRCA-Mutated Metastatic Breast CancerAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing: May 2018 - Volume 118 - Issue 5 - p 21-22 doi: 10.1097/01.NAJ.0000532827.55271.55 Buy Metrics Abstract Lynparza (olaparib tablets) is now approved for the treatment of inherited BRCA-mutated, human epidermal growth factor receptor 2–negative metastatic breast cancer. Drugs and other substances that greatly increase or decrease the activity of the cytochrome P-450 (CYP) isoenzyme CYP3A should be avoided when taking Lynparza. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.